Pioglitazone for the treatment of NASH in patients with prediabetes or type 2 diabetes mellitus

I read with great interest the recent comprehensive review by Rotman and Sanyal.1 I would just like to point out an error in table 1 (row 1), where the authors inadvertently state that pioglitazone has shown histological benefit only in secondary analyses and not been studied in patients with diabetes and nonalcoholic fatty liver disease (NAFLD). Benefit with the thiazolidinedione has been reported for the primary histological outcome in two randomised controlled trials (RCTs) in patients with prediabetes or type 2 diabetes mellitus (T2DM). This is most likely an oversight as in the text the authors quote our early proof-of-concept study by Belfort et al ( ref. 2; reference 28 in the review) where pioglitazone improved the NAFLD activity score (NAS) in 73% compared with 24% of placebo-treated patients (p<0.001) in patients with either prediabetes or T2DM. However, the authors missed including a more recent...

https://ift.tt/2sNrP2V